Ozempic
1.34 mg/mL · Injection, Solution
- Prescription only
- GLP-1 Receptor Agonist
- Active substance
- Semaglutide
- Made by
- Novo Nordisk Pharmaceutical Industries, LP
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
This information is not included in the verified source. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Ozempic). It describes the substance, not this exact product.
Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1.
Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1.
Approximately 3% of the dose is excreted in the urine as intact semaglutide.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-30
Safety of the active substance
From the US prescribing label for the same active substance (Ozempic). It describes the substance, not this exact product.
WARNING: RISK OF THYROID C-CELL TUMORS.
- OZEMPIC is contraindicated in patients with:.
- A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions ( 5.1 )]..
- A serious hypersensitivity reaction to semaglutide or to any of the excipients in OZEMPIC.
- Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with OZEMPIC [see Warnings and Precautions ( 5.8 )]..
The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Novo Nordisk Pharmaceutical Industries, LP |
|---|---|
| Active substance | Semaglutide |
| Used in | Digestion, stomach, diabetes and nutrition |
| Strength | 1.34 mg/mL |
| Form | Injection, Solution |
| Route | Subcutaneous |
| Packs | 1 SYRINGE, PLASTIC in 1 CARTON / 3 mL in 1 SYRINGE, PLASTIC |
| NDC | 0169-4130 |
Source: NDC Directory · 2026-09-13 · not reviewed by a clinician
Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).
Other strengths and forms
9 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- Injection, Solution6 products
.68 mg/mL2
.68 mg/mL · 2 companies
1.34 mg/mL2
1.34 mg/mL · 2 companies
- A-S Medication Solutions
- Novo Nordisk Pharmaceutical Industries, LP · this page
2.68 mg/mL2
2.68 mg/mL · 2 companies
- Tablet3 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.